Literature DB >> 21878894

Targeted therapies: Front-line therapy in lung cancer with mutations in EGFR.

Lorenza Landi, Federico Cappuzzo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21878894     DOI： 10.1038/nrclinonc.2011.135

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  6 in total

1.  Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study.

Authors:  Giuseppe Giaccone; Marielle Gallegos Ruiz; Thierry Le Chevalier; Nick Thatcher; Egbert Smit; Jose Antonio Rodriguez; Pasi Janne; Dalila Oulid-Aissa; Jean-Charles Soria
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

2.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

3.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

Authors:  Tetsuya Mitsudomi; Satoshi Morita; Yasushi Yatabe; Shunichi Negoro; Isamu Okamoto; Junji Tsurutani; Takashi Seto; Miyako Satouchi; Hirohito Tada; Tomonori Hirashima; Kazuhiro Asami; Nobuyuki Katakami; Minoru Takada; Hiroshige Yoshioka; Kazuhiko Shibata; Shinzoh Kudoh; Eiji Shimizu; Hiroshi Saito; Shinichi Toyooka; Kazuhiko Nakagawa; Masahiro Fukuoka
Journal:  Lancet Oncol       Date:  2009-12-18       Impact factor: 41.316

4.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

Authors:  Caicun Zhou; Yi-Long Wu; Gongyan Chen; Jifeng Feng; Xiao-Qing Liu; Changli Wang; Shucai Zhang; Jie Wang; Songwen Zhou; Shengxiang Ren; Shun Lu; Li Zhang; Chengping Hu; Chunhong Hu; Yi Luo; Lei Chen; Ming Ye; Jianan Huang; Xiuyi Zhi; Yiping Zhang; Qingyu Xiu; Jun Ma; Li Zhang; Changxuan You
Journal:  Lancet Oncol       Date:  2011-07-23       Impact factor: 41.316

5.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

6.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245
  6 in total
  6 in total

1.  Pituitary adenylate cyclase-activating polypeptide causes tyrosine phosphorylation of the epidermal growth factor receptor in lung cancer cells.

Authors:  Terry W Moody; Nauramy Osefo; Bernardo Nuche-Berenguer; Lisa Ridnour; David Wink; Robert T Jensen
Journal:  J Pharmacol Exp Ther       Date:  2012-03-02       Impact factor: 4.030

Review 2.  Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer.

Authors:  Shanbeh Zienolddiny; Vidar Skaug
Journal:  Lung Cancer (Auckl)       Date:  2011-12-29

3.  Estimating the direct and indirect costs of lung cancer: a prospective analysis in a Greek University Pulmonary Department.

Authors:  Vasiliki Zarogoulidou; Efharis Panagopoulou; Despina Papakosta; Dimitris Petridis; Konstantinos Porpodis; Konstantinos Zarogoulidis; Paul Zarogoulidis; Malamatenia Arvanitidou
Journal:  J Thorac Dis       Date:  2015-02       Impact factor: 2.895

4.  Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective.

Authors:  Irfan Cicin; Ergun Oksuz; Nuri Karadurmus; Simten Malhan; Mahmut Gumus; Ulku Yilmaz; Levent Cansever; Halit Cinarka; Erdogan Cetinkaya; Murat Kiyik; Ahmet Ozet
Journal:  Health Econ Rev       Date:  2021-06-26

5.  The cost of treating advanced non-small cell lung cancer: estimates from the chinese experience.

Authors:  Xiaohui Zeng; Jonathan Karnon; Siying Wang; Bin Wu; Xiaomin Wan; Liubao Peng
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

6.  Somatic mutations in exocrine pancreatic tumors: association with patient survival.

Authors:  P Sivaramakrishna Rachakonda; Andrea S Bauer; Huaping Xie; Daniele Campa; Cosmeri Rizzato; Federico Canzian; Stefania Beghelli; William Greenhalf; Eithne Costello; Michaela Schanne; Anette Heller; Aldo Scarpa; John P Neoptolemos; Jens Werner; Markus Büchler; Jörg D Hoheisel; Kari Hemminki; Nathalia Giese; Rajiv Kumar
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.